Form 4: Director Siddharth Kaul Receives Immunocore Option Grant
Statement of Changes in Beneficial Ownership
Director Siddharth Kaul was granted 27,492 stock options in Immunocore Holdings plc as part of an equity compensation award.
Summary
- Director Siddharth Kaul received a grant of 27,492 share options on May 27, 2026.
- The options have an exercise price of $28.52 per share.
- The options are set to expire on May 26, 2036.
- Vesting occurs on the earlier of May 27, 2027, or the day before the next annual general meeting.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation with no material impact on the company's operational outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the underlying ordinary shares.
- Potential for the options to remain underwater if the share price does not exceed the $28.52 exercise price.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of an equity grant to a director.
Industry Context
StockSavvy.ai notes that equity grants to non-executive directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.
Comparison to Industry Standards
- The use of annual vesting cycles for director equity is consistent with standard practices for NASDAQ-listed biotechnology firms.
- The exercise price reflects the market value at the time of the grant, adhering to standard regulatory requirements for incentive compensation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of stock options to Director Siddharth Kaul. | 05/27/2026 | Standard alignment of director incentives with shareholder interests. |
Stakeholder Impact
- Shareholders: Minor dilution impact upon future exercise of options.
- Director: Increased financial stake in the company's long-term performance.
Next Steps
- Vesting of the options on May 27, 2027, or the day prior to the next annual general meeting.
Key Dates
| Date | Description |
|---|---|
| 05/27/2026 | Date of the option grant transaction. |
| 05/27/2027 | Primary vesting date for the option award. |
| 05/26/2036 | Expiration date of the option award. |
Keywords
Immunocore, IMCR, Director Compensation, Stock Options, Insider Transaction, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.